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Abstract
Transforming growth factor-beta (TGF-β)/SMAD signaling is a key growth regulatory pathway often dysregulated in ovarian cancer and other
malignancies. Although loss of TGF-β–mediated growth inhibition has been shown to contribute to aberrant cell behavior, the epigenetic con-
sequence(s) of impaired TGF-β/SMAD signaling on target genes is not well established. In this study, we show that TGF-β1 causes growth
inhibition of normal ovarian surface epithelial cells, induction of nuclear translocation SMAD4, and up-regulation of ADAM19 (a disintegrin and
metalloprotease domain 19), a newly identified TGF-β1 target gene. Conversely, induction and nuclear translocation of SMAD4 were negligible
in ovarian cancer cells refractory to TGF-β1 stimulation, and ADAM19 expression was greatly reduced. Furthermore, in the TGF-β1 refractory
cells, an inactive chromatin environment, marked by repressive histone modifications (trimethyl-H3K27 and dimethyl-H3K9) and histone dea-
cetylase, was associated with the ADAM19 promoter region. However, the CpG island found within the promoter and first exon of ADAM19
remained generally unmethylated. Although disrupted growth factor signaling has been linked to epigenetic gene silencing in cancer, this is the
first evidence demonstrating that impaired TGF-β1 signaling can result in the formation of a repressive chromatin state and epigenetic sup-
pression of ADAM19. Given the emerging role of ADAMs family proteins in growth factor regulation in normal cells, we suggest that epigenetic
dysregulation of ADAM19 may contribute to the neoplastic process in ovarian cancer.
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Introduction
Transforming growth factor-beta (TGF-β) 1, 2, and 3 are potent cy-
tokines controlling a plethora of physiological processes including cell
growth, differentiation, apoptosis, developmental fate, and embryo-
genesis in mammals [1]. Transforming growth factor-beta ligands,
through binding to transforming growth factor-beta receptor 1 or
2 (TGFβR1 or TGFβR2), initiate a signal transduction cascade
and result in activation of SMAD transcription factors. Of the five
SMADs regulated by TGFβRs, activated SMAD2 and SMAD3 fur-
ther associate with SMAD4 and subsequently translocate into the
nucleus where they bind to target promoters and modulate transcrip-
tion of SMAD-specific target genes [2].
The TGF-β signaling pathway plays a central role in a wide range
of cellular processes, including the regulation of mammalian ovula-
tion [3,4]. With each ovulation, the ovarian surface epithelium
(OSE) covering the ovary is subject to rupture and repair, a process
composed of hallmarks of a wound/healing event including inflam-
mation [4]. Rupture of the OSE is mediated by growth factors fol-
lowed by subsequent repair at the site of ovulation and OSE
“overproliferation” [3]. It is suggested that the growth inhibitory ef-
fect of TGF-β on the OSE, which includes activation of growth sup-
pression genes (e.g., cyclin-dependent kinase inhibitor p15Ink4B [5]),
may play a key role in preventing the overproliferation of OSE
during normal ovulatory cycles [3,4]. Because dysregulation of
TGF-β signaling has been associated with loss of growth inhibition
of the OSE [3], it is postulated that such a signaling plays key roles
leading to transformation and subsequent ovarian tumorigenesis [6].
In this scenario, the transformed OSE becomes refractory to TGF-β–
mediated growth suppression [7,8]. However, in more advanced
stages of development and disease progression, interplay between
TGF-β and other growth factor transduction pathways has been
shown to further promote tumor proliferation and invasion [9,10].
Our previous genome-wide screening using chromatin immuno-
precipitation (ChIP; through anti–SMAD4 antibody) in conjunction
with microarray technology (known as ChIP-chip) has identified
ADAM19 (a disintegrin and metalloprotease domain 19) [11] as a
TGF-β/SMAD target gene in OSE (Qin H, Chan M, Liyanarachchi
S, Balch C, Potter D, Souriraj I, Cheng A, Agosto-Perez F, Yan P,
Lin H, et al. (submitted). Modeling SMAD regulatory modules by
integrative datamining of ChIP-chip and gene expression profiles.).
ADAMs are a family of membrane metalloproteinases involved
in various physiological processes, including cell adhesion, cell fu-
sion, cell migration, membrane protein shedding, and proteolysis
[12,13]. A role for ADAMs in malignancy and tumor development
has recently highlighted [13–15]. Certain ADAM family members
have been shown to be overexpressed in various cancers, including
hepatocellular [16], colorectal [17], prostate [18], breast [18–20],
and ovarian [21], indicating that dysregulated ADAMs may govern
a common event in human malignancy. The precise role of ADAMs
in cancer, however, remains largely unknown.
Recently, aberrant ADAM19 expression by epigenetic mechanisms
has been reported [11]. Unlike genetic mutations, epigenetic mod-
ulation does not involve changes of primary nucleotide sequences
but has a profound effect on gene promoter activity [22]. Cytosine
methylation, a key epigenetic event mediated by DNA methyl-
transferases, is frequently found in promoter CpG islands of inactive
genes in cancer [23]. Conversely, posttranslational modifications of
chromatin, mediated in part by histone methyltransferases and de-
acetylases, are known to mark transcriptionally silent genes [24].
In cancer cells, such epigenetic components act in concert to aber-
rantly repress genes responsible for growth suppression and genomic
stability [25].
In the present study, we show that TGF-β1–refractory ovarian can-
cer cells harbor inadequate SMAD4 nuclear translocation and thus
impair ADAM19 induction. Rather than promoter CpG island hyper-
methylation, we further suggest that two repressive histone methyla-
tion marks (trimethyl-H3K27 and dimethyl-H3K9) and histone
deacetylase (HDAC) contribute to ADAM19 down-regulation. This
is the first report demonstrating that aberrant TGF-β1 signaling can
result in formation of a repressive chromatin environment at a target
gene in ovarian cancer. These findings may allow for the further un-
derstanding how complex epigenetic patterns, involving histone modi-
fications, contribute to epithelial ovarian cancer, a highly fatal disease.
Materials and Methods
Cell Culture, Growth Assays, and Epigenetic Treatments
All studies involving ovarian epithelial cells were approved by the
Institutional Review Boards of Indiana University and the Ohio State
University. Normal OSE (nOSE) cells were acquired from patients
during surgery for benign gynecologic disease, as previously described
[26,27]. To confirm epithelial purity, nOSE cells were stained for
cytokeratins and vimentin, as described [28,29]. Immortalized
OSE (IOSE) cells were derived by transducing the catalytic subunit
of human telomerase and the papilloma virus subunit E7 into pri-
mary ovarian epithelial cells, as described [30]. Both IOSE and
nOSE cells were maintained in a 1:1 mixture of media 199 (Sigma,
St Louis, MO) and 105 (Sigma) supplemented with 10% fetal bo-
vine serum (FBS; Invitrogen, Carlsbad, CA), 400 ng/ml hydrocorti-
sone (Sigma), 10 ng/ml epidermal growth factor (EGF), and 50 U/
ml penicillin/streptomycin (Invitrogen). The A2780 cell line [31]
was maintained in DMEM (Invitrogen) supplemented with 10%
FBS and 50 U/ml penicillin/streptomycin, whereas CP70, MCP2,
and MCP3 cells (cisplatin-resistant sublines of A2780) [32] were
propagated in RPMI-1640 (Invitrogen) supplemented with 10%
FBS and 50 U/ml penicillin/streptomycin. SKOV3 cells [26,31]
were maintained in McCoy’s 5A (Invitrogen) supplemented with
10% FBS, 50 U/ml penicillin/streptomycin, 1× nonessential amino
acid, and 0.01 M of HEPES.
The growth-suppressive effect of TGF-β1 was assessed using a pre-
viously described protocol [33]. Briefly, 5 × 104 cells were seeded into
35-mm plate. After an overnight incubation, cells were cultivated
with fresh medium supplemented with TGF-β1 (10 ng/ml; Sigma)
or vehicle (DMSO) and with medium replacement every 3 days. Cell
numbers were determined using a hemacytometer. For cancer cell
lines, the growth response to TGF-β1 was determined by using Cell-
Titer 96 Aqueous One Solution Cell Proliferation Assay kit (Promega,
Madison, WI). Cells (∼1000) were cultivated in 96-well plates
with or without 10 ng/ml TGF-β1 for 4 days. Relative cell numbers
were assessed by using a 96-well plate reader with an absorbance set
at 490 nm.
For epigenetic studies, cells were treated with 5-aza-2′-deoxycytidine
(DAC, 0.5 μM; Sigma) with a medium change every 24 hours. After
4 days, cells were either treated with TGF-β1 (10 ng/ml, 3 hours)
and harvested or treated with trichostatin A (TSA, 0.5 μM; Sigma)
for an additional 12 hours before a TGF-β1 stimulation. Cells were
collected for DNA and RNA isolation (described below).
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Preparation of Cell Extracts and Western Immunoblots
Cells were grown to confluence in growth media, washed twice
with phosphate-buffered saline (PBS), and then cultured for an ad-
ditional 16 hours in the appropriate medium containing 0.1% FBS.
Cells were then left either untreated or treated with 10 ng/ml TGF-
β1 for 2 hours. Whole-cell and nuclear extracts were harvested essen-
tially as described previously [34,35], except that PhosStop reagent
(Roche, Indianapolis, IN) was added to the whole-cell extract buffer.
The whole-cell extracts were prepared by harvesting cells in 1× SDS
lysis buffer with PhosStop and were sonicated on ice. The resultant
insoluble contents were discarded by centrifugation, whereas the sol-
uble supernatant was saved for further studies. Enriched nuclear frac-
tions were prepared using a nuclear extraction kit (Active Motif,
Carlsbad, CA) according to the protocol provided by the manufac-
turer. Whole-cell and nuclear supernatant protein concentrations
were quantified with the DC protein assay (BioRad, Hercules,
CA). Proteins in whole-cell and nuclear extracts (30 μg per lane)
were separated by SDS-PAGE and transferred to polyvinylidene
difluoride membranes. Membranes were probed with mouse mono-
clonal antibodies recognizing either SMAD 4 (sc-7966, Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) or glyceraldehyde phosphate
dehydrogenase (GAPDH; Chemicon International, Temecula, CA).
Primary antibody was detected by horseradish peroxidase–conjugated
secondary antibody (KPL, Inc., Gaithersburg, MD) and visualized
using SuperSignal West Pico chemiluminescent substrate (Pierce Bio-
technology, Rockford, IL).
Quantitative ChIP–Polymerase Chain Reaction and Reverse
Transcription–Polymerase Chain Reaction
Chromatin immunoprecipitation–polymerase chain reaction
(PCR) was performed as described [36]. Cultured cells (2 × 106)
were cross-linked with 1% formaldehyde and then washed with
PBS in the presence of protease inhibitors. Cells were homogenized,
and their chromatin was subjected to ChIP reactions using a com-
mercially available kit (Millipore, Temecula, CA; formerly Upstate
Biotechnology, Lake Placid, NY) and antibodies against SMAD4,
DNMT1 (Cell signaling Technology, Danvers, MA), trimethyl-
H3K27, dimethyl-H3K9, or HDAC1 (Millipore), respectively. Fold
enrichment of amplified DNA by ChIP was assessed using previously
described protocols [36]. Specific primers for amplification are listed
in Table W1. Quantitative reverse transcription–polymerase chain
reaction (RT-PCR) was performed as described previously [36]. To
remove potential contaminating DNA from the RT-PCR mixture,
2 μg of total RNA was treated with DNase I (Invitrogen) before re-
verse transcribing with Superscript II reverse transcriptase (Invitrogen).
The relative gene expression level was determined by comparing the
threshold cycle (C t) of the test gene against the C t of GAPDH in a
given sample, as previously described [36].
RNA Interference Studies
Immortalized OSE cells (2 × 105) were seeded in a six-well plate
overnight and then transfected with predesigned siRNA (Ambion,
Austin, TX) against SMAD4 (siRNA ID: 5365), GATA 1 (siRNA
ID: 3197), GATA 4 (siRNA ID: 215764), or negative control (siRNA
ID 4613) at a concentration of 25 nM, as suggested by the manu-
facturer (TransIT-TKO Transfection Reagent; Mirus, Madison, WI).
After 48 hours, cells were treated with TGF-β1 (10 ng/ml for 3 hours),
and total RNA was harvested for quantitative RT-PCR analysis.
Immunofluorescence Staining
Cells were seeded onto chamber slides (BD Biosciences, San Jose,
CA) at approximately 1000 cells per well for 3 days before staining.
On the second day, cells were washed twice with PBS and cultivated
in the appropriate medium containing 0.1% FBS for an additional
16 hours. On the third day, cells were either left untreated or treated
with TGF-β1 (10 ng/ml, 2 hours), washed twice with PBS at room
temperature, and then fixed with 4% paraformaldehyde for 10 min-
utes. Fixed cells were washed three times with PBS at room tem-
perature and then permeabilized with 0.1% Triton X-100 for
10minutes. After permeabilization, cells were washed (1× PBS at room
temperature), blocked with 10% normal goat serum (Vector Laborato-
ries, Burlingame, CA) for 30 minutes, and incubated with antihuman
SMAD4 monoclonal antibody (sc-7966x; Santa Cruz Biotechnology;
diluted 1:2000 in PBS supplemented with 2% goat serum). After in-
cubation at room temperature for 1 hour, cells were washed, incubated
with fluorescein isothiocyanate–goat antimouse secondary antibody
(Zymed, San Francisco, CA; 1:400 dilution in PBS containing 2%
goat serum) for 30 minutes at room temperature, washed, stained with
DAPI nuclear stain (Molecular Probes, Eugene, OR), and then
mounted with Vectashield mounting medium (Vector Laboratories).
Images were captured at a magnification of ×200 using a fluorescence
microscope (Carl Zeiss Microimaging Inc., Thornwood, NY).
Assay for Autocrine Production of TGF-β
Secreted TGF-β1 in the culture supernatant were quantified by
colorimetric ELISA Quantikine immunoassays (R&D Systems,
Minneapolis, MN) according to the instructions provided by the
manufacturer. Briefly, 1 × 104 cells were plated in a 24-well plate.
The next day, media were changed to serum-free medium containing
200 ng/ml BSA for 24 hours. Media were then harvested and acid-
activated for the quantitative determination of TGF-β1 levels.
Mutational Analysis of SMAD4
Polymerase chain reaction amplification of specific exon regions of
SMAD4 was carried out using platinum Taq DNA polymerase with
high fidelity (Invitrogen). Polymerase chain reaction and sequencing
primers are listed in Table W1. Polymerase chain reaction products
were purified using the QIAquick PCR purification kit (Qiagen,
Valencia, CA) and analyzed by automated sequencing using the
ABI 3730 DNA sequence analyzer (Applied Biosystems, Foster City,
CA). Sequence analysis was performed using the Chromas Lite software
(Technelysium Pty Ltd, Tewantin, Australia).
Bisulfite Sequencing Analysis
Bisulfite-converted DNA was amplified using specific primers
(Table W1) for promoter region of ADAM19. The resultant PCR
products were cloned into the Topo TA cloning kit (Invitrogen).
Ten randomly picked clones were sequenced using the ABI 3730
DNA sequence analyzer (Applied Biosystems) and analyzed using
the BIQ analyzer [37].
Statistical Analysis
The significance of cell growth, ChIP-PCR, and RT-PCR results
was assessed using Mann-Whitney U tests or Student’s t tests in-
cluded in the statistical software SPSS (version 10.0; SPSS Inc.,
Chicago, IL). P < .05 was considered statistically significant.
910 Epigenetic Repression of ADAM19 Chan et al. Neoplasia Vol. 10, No. 9, 2008
Results
Differential Expression of ADAM19 in TGF-β1–Responsive
and TGF-β1–Refractory Ovarian Epithelial Cells
To examine the effect of TGF-β on ovarian cell growth, normal and
ovarian cancer cells were treated with TGF-β and cell proliferation
assays were performed. Significant (P < .05) growth inhibition of
IOSE cells by TGF-β was observed, (Figure 1A). However, unlike
IOSE, the growth-inhibitory effect of TGF-β on ovarian cancer cell
lines was negligible, with the exception of SKOV3 (Figure 1A). On
the basis of our recent ChIP-chip analysis identifying ADAM19 as
a candidate TGF-β/SMAD4 target gene in OSE (Qin H, Chan
M, Liyanarachchi S, Balch C, Potter D, Souriraj I, Cheng A, Agosto-
Perez F, Yan P, Lin H, et al. (submitted). Modeling SMAD regulatory
modules by integrative datamining of ChIP-chip and gene expression
profiles.), it was of interest to examine expression levels of ADAM19
in these cell lines. Despite elevated basal level, further induction
of ADAM19 after TGF-β stimulation was observed in IOSE and
SKOV3 cells (approximately 2- and 1.3-fold, respectively) deter-
mined by quantitative RT-PCR (Figure 1B). In contrast, dramatically
lower or undetectable ADAM19 expression (Figure 1B) was seen in the
ovarian cancer cell lines whose growth rates were minimally impeded
by TGF-β1 treatment (Figure 1A). Further, we found no effect of
TGF-β1 treatment on autocrine secretion of TGF-β1 (data not
shown), suggesting that down-regulation of ADAM19 may result from
aberrant TGF-β1 signaling.
To further examine mechanism, cellular localization and levels of
SMAD4 were assessed by immunofluorescence staining and Western
blot analyses. In OSE cells showing the greatest response to TGF-β1
treatment (Figure 1), nuclear translocation of SMAD4 was appar-
ent (Figure 2, A–C ). Interestingly, ADAM19-overexpressing SKOV3
retained an intermediate-to-high level of SMAD4 in the nuclear
compartment (Figure 2C ), regardless of the presence or absence of
TGF-β1 stimulation (Figure 2, B and C ) and with slightly elevated
nuclear allocation after induction (Figure 2C ). To a lesser extent,
MCP3 showed moderate SMAD4 nuclear localization (Figure 2, B
and C ), and this cell line also showed some degree of ADAM19 in-
duction after TGF-β1 treatment (Figure 1B). In contrast, in cell lines
displaying a low level of ADAM19 expression (MCP2, A2780, and
CP70), SMAD4 nuclear translocation after TGF-β1 stimulation was
negligible (Figure 2, B and C ), suggesting that a low level of SMAD4
in the nuclear compartment is insufficient to induce ADAM19 ex-
pression. Taken together, our data suggest that in response to TGF-
β signaling, an adequate level of nuclear SMAD4 is important for
up-regulating ADAM19 in OSE cells, although the possibility that
ADAM19 may be driven by another SMAD4-independent mecha-
nism [38] cannot be excluded.
SMAD4 and GATA4 Play a Role in TGF-β–Mediated
Induction of ADAM19
Analysis of the ADAM19 gene promoter revealed two potential
TGF-β/SMAD4 binding sites (SBE-1 and SBE-2) within 400-bp
upstream from the transcription start site (Figure 3A). We used
ChIP-PCR to further investigate the mechanism underlying TGF-
β–mediated ADAM19 expression (Qin H, Chan M, Liyanarachchi
S, Balch C, Potter D, Souriraj I, Cheng A, Agosto-Perez F, Yan P,
Lin H, et al. (submitted). Modeling SMAD regulatory modules by
integrative datamining of ChIP-chip and gene expression profiles.)
and the roles these putative sites play. TGF-β1 stimulation of IOSE
cells resulted in SMAD4 binding to both SBEs (Figure 3B for SBE-1;
data not shown for SBE-2) and accompanied by a progressive
increase of ADAM19 mRNA levels (up to sixfold at 12 hours of
stimulation; Figure 3C ). Conversely, because binding sites for tran-
scription factors GATA-1 and GATA-4 were also predicted in the
promoter region of ADAM19 (Qin H, Chan M, Liyanarachchi S,
Balch C, Potter D, Souriraj I, Cheng A, Agosto-Perez F, Yan P,
Lin H, et al. (submitted). Modeling SMAD regulatory modules by
integrative datamining of ChIP-chip and gene expression profiles.),
we conducted siRNA knockdown experiments to investigate whether
cooperation among these factors might contribute to TGF-β–mediated
ADAM19 up-regulation. Single knockdown of SMAD4 caused a
slight but statistically insignificant decrease in the ADAM19 expres-
sion (Figure 3D). However, the combined knockdown of SMAD4
plus GATA-4 decreased (P < .05) expression of ADAM19, suggesting
that SMAD4 and GATA4 cooperate in TGF-β–mediated ADAM19
induction. In contrast, simultaneous knockdown of GATA-1 and
SMAD4 enhanced TGF-β–mediated ADAM19 expression, in agree-
ment with the previous finding demonstrating GATA-1 as a transcrip-
tional repressor [39].
Figure 1. Analysis of cell growth and ADAM19 expression in ovar-
ian cells. (A) Growth response of IOSE cells (immortalized OSE)
and ovarian cancer cell lines to TGF-β1 (10 ng/ml) was conducted
as described in the Materials and Methods section. *P < .05. (B)
mRNA were isolated from untreated (control) and TGF-β1–treated
cells and converted into cDNA for amplification with specific prim-
ers for ADAM19. Relative levels of expression after quantitative
RT-PCR analysis were calculated and compared to the untreated
IOSE (set as 100%).
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Impaired SMAD4 Nuclear Localization Is Associated with
Low TGFβR2 Expression in TGF-β1 Refractory Ovarian
Cancer Cells
To further investigate the mechanistic cause leading to impaired
SMAD4 translocation and TGF-β1 signaling in ovarian cancer cells,
we examined steady-state levels of SMAD4 mRNA in the cells. Ab-
errant SMAD4 translocation seemed to be poorly related to the basal
expression of SMAD4 at either the mRNA (Figure 4A) or protein
(Figure 2A) levels. Next, we examined the steady-state mRNA levels
of two TGF-β receptors, TGFβR1 and TGFβR2, in ovarian cancer
cell lines. Whereas no pattern of basal expression in TGFβR1 (Fig-
ure 4B), SMAD4 (Figures 2A and 4A), or ADAM19 (Figure 1B) was
apparent across the cell lines, the TGF-β1–refractory cells (MCP2,
A2780, and CP70) displayed low TGFβR2 expression (Figure 4C ).
Further, these same cell lines also exhibited impaired growth inhibi-
tion (Figure 1A), SMAD4 nuclear translocation (Figure 2, A–C ) and
ADAM19 induction (Figure 1B) upon TGF-β1 treatment. Yet, this
relationship was less apparent in MCP3 and might be regulated by
an additional mechanism(s) other than TGFβR2. Nevertheless, our
data support the possibility that a reduction in this specific receptor
(TGFβR2) may contribute, in part, to disruption of TGF-β1 signal-
ing and SMAD4-mediated transcriptional activation of ADAM19
in ovarian cancer cells. Our observations are in general agreement
with a previous study, which showed that TGFβR2 levels might
dictate the ability of hepatocelluar carcinoma cells to internalize
SMAD4 [40].
Although SMAD4 mutations are uncommon in ovarian cancer, we
conducted sequence analysis for two mutational hotspots in exons 9
and 11 frequently found in other solid tumors [41]. Except for a TA
insertion in codon 404 of exon 9 in A2780 cells and an intronic T to
C transition in SKOV3 cells, no major SMAD4 mutations were
found (Table W2). Thus, it is unlikely that a genetic defect was
the underlying cause contributing to impaired nuclear localization
function of SMAD4.
Figure 2. Nuclear localization of SMAD4protein in ovarian cell lines stimulatedwith TGF-β1. (A)Western blot analysis of normal OSE (nOSE
and IOSE) and ovarian cancer cell lines (SKOV3, MCP3, MCP2, A2780, and CP70). Cells were serum-starved for 16 hours and treated with
TGF-β1 (10 ng/ml).Whole-cell (W) or nuclear (N) extractswere harvested; 30 μg of each extract typewas run on SDS-PAGE and probedwith
anti-SMAD4. To assure equal quantity of sample loading, antibody for glyceraldehyde-3-phosphate dehydrogenase (GAPDH; above) and
Coomassie-stained membranes (Figure W1) were used. All experiments were repeated twice; representative blots are shown. Quantifi-
cation is shown in the histogram with normalization to GAPDH. (B) Immunofluorescence analysis of SMAD4 nuclear staining in ovarian
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Figure 2. (continued) (B) Immunofluorescence analysis of SMAD4 nuclear staining in ovarian cancer cell lines. Cells were seeded in slide
chambers and then treated with either TGF-β1 or DMSO (control). Cells were then stained with anti-SMAD4 monoclonal antibody, fol-
lowed by staining with fluorescein isothiocyanate–goat antimouse IgG (green) and counterstaining with DAPI (nuclei stained in blue).
Representative results for selected cell lines are shown. (C) Semiquantitative analysis of nuclear staining of SMAD4. The number of cells
(n = 50) showing different intensities of nuclear staining in control (−) or TGF-β1 (+) was independently counted by two individuals.
Intensity levels of staining were categorized as strong “+++,” intermediate “++,” or weak “+.”
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Figure 3. Analysis of SMAD4 binding and ADAM19 expression in IOSE cells, in response to TGF-β1 treatment. (A) Schematic diagram
depicting the locations of CpG sites and the positions of putative SMAD4-binding elements (SBE-1 and SBE-2), GATA-1, GATA-4, NF-κB,
and VDRE (vitamin D response element) with respect to the transcriptional start site (TSS) of the ADAM19 gene. Underline indicates the
location where ChIP–PCR of SBE was conducted. Arrowheads indicate primer locations used for bisulfite sequencing analysis. Regions
for chromatin profiling by ChIP-PCR (used in Figure 5B) are also indicated by underlines. (B) Quantitative ChIP-PCR analysis of SMAD4
binding. Immunoprecipitation was conducted with an antibody against SMAD4, and the pull-down DNA product was used to amplify
a region of ADAM19 containing a putative SBE-1. The level of binding was compared to that of total input DNA. (C) Time-course analy-
sis of ADAM19 mRNA levels by quantitative RT-PCR. mRNA were isolated at the indicated time points (0-12 hours) after TGF-β1 treat-
ments and converted into cDNA for amplification with primers specific for ADAM19. The relative level of expression was calculated and
was compared to the one in the untreated control (set as 1). (D) Quantitative RT-PCR analysis of the mRNA levels of ADAM19 in siRNA
knock-down experiments. TGF-β1–treated or –untreated IOSE cells were transfected with predesigned siRNA. Reverse transcription–
polymerase chain reaction was used to amplify ADAM19 cDNA after siRNA treatments, and mRNA levels were quantified. Error bars
indicate SD calculated from triplicates. *P < .05. **P < .01.
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ADAM19 Expression Is Repressed by Epigenetic
Modifications in Ovarian Cancer Cells with Impaired
SMAD4 Nuclear Translocation
Previous studies [42,43] including ours [44] have demonstrated
that dysregulated upstream signaling events can lead to epigenetic
modifications of downstream target genes and subsequent down-
regulation of expression. To address whether disrupted TGF-β1 sig-
naling may lead to epigenetic silencing of ADAM19, we examined the
proximal promoter region of ADAM19 for epigenetic modifications.
Bisulfite sequencing was first conducted to determine the methylation
status of a CpG island spanning a 600-bp region in the promoter and
first exon region of ADAM19 (Figure 5A). High-resolution mapping
of 62 CpG sites revealed an overall lack of prominent methylation in
MCP3, MCP2, A2780, and CP70 cell lines (which also harbor low
basal level of ADAM19 expression; Figure 1B). Yet, few methylated
sites were found in the distal promoter region of A2780 and CP70 cell
lines, suggesting that an aberrant methylation event might occur
further upstream from this CpG island. However, additional bisulfite
sequencing analysis demonstrated that <10% of the CpG sites were
methylated in the region further upstream (data not shown). In
agreement with the bisulfite sequencing results, lack of DNMT1
binding to the ADAM19 CpG island was observed in the panel of cell
lines (except A2780; Figure W2). On the basis of these findings, we
conclude that neither DNA methylation nor binding to DNMT1
plays a significant role in the suppression of ADAM19 in these ovarian
cancer cells.
We then analyzed the ADAM19 proximal promoter and the first
exon for the presence of repressive chromatin marks by quantitative
ChIP-PCR. Trimethyl-H3K27 is a known histone modification
mark associated with an inactive chromatin state [45]. We observed
significant (P < .01) enrichment of trimethyl-H3K27 in both the
promoter and first exon of ADAM19 in those cell lines showing tran-
scriptional repression (Figure 5B). Similarly, we observed significant
(P < .05) enrichment of two additional repressive histone marks,
dimethyl-H3K9 (both the promoter and first exon) and HDAC1
(first exon only), in the ADAM19 locus (Figure 5B). Treatment with
either an HDAC inhibitor, TSA, or a demethylating agent, DAC,
both of which have been shown to remove these repressive marks
[46,47], partially restored ADAM19 expression (Figure 6, A and
B). Interestingly, cells (A2780 and CP70) with a high level of the
repressive marks and HDAC binding showed a prominent ADAM19
reactivation, after TSA treatment (Figure 6A). Yet, combinatorial
treatment did not result in a synergistic effect on ADAM19 reactiva-
tion (data not shown). Perhaps, both drugs acted on the same mech-
anism to relieve epigenetic repression in this particular scenario.
Taken together, these results suggested that impaired TGF-β signal-
ing conferred aberrant histone marks, which repressed the expression
of ADAM19 in these refractory cell lines.
Discussion
Although transcriptional repression of tumor-suppressor genes by
epigenetic control is a common occurrence in cancer [22], how epi-
genetically silenced tumor suppressors and other genes are established
and maintained remains to be elucidated. On the basis of the present
findings, we propose that disruption of an upstream regulator may
result in epigenetic silencing of a downstream target gene. In ovarian
cancer cells, we observed that epigenetic-mediated repression of
ADAM19, a downstream target of TGF-β signaling, is in part medi-
ated by impaired nuclear translocation of SMAD4, a key component
of the TGF-β signaling pathway. In support of this possibility, a sim-
ilar phenomenon was recently reported in breast carcinogenesis. Im-
paired SMAD4 nuclear localization, in conjunction with epigenetic
silencing of several members of TGF-β signaling pathway by chroma-
tin remodeling, converted primary human mammary epithelial cells
into a premalignant state [48]. As dysregulation of ADAMs in vari-
ous tumors has been described [16–21], we suggest that epigenetic re-
pression of ADAM19 may contribute to ovarian cancer progression.
Our findings on this novel epigenetic mechanism for altering
expression of ADAM19 are further supported by previous studies
[42–44,49]. For example, Ren et al. [42] demonstrated that impaired
Figure 4. Expression levels of SMAD4 and two TGF-β receptors,
TGFβR1 and TGFβR2. Quantitative RT-PCR analysis was carried
out on ovarian cell lines to assess the expression levels of (A)
SMAD4, (B), TGFβR1, and (C) TGFβR2.
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Figure 5. Epigenetic modifications of ADAM19. (A) Bisulfite sequencing analysis of ADAM19 in ovarian cancer cells. The locations of
primers used to amplify bisulfite-treated DNA are indicated by the arrowheads in Figure 3A. Black (filled) circle indicates methylation,
whereas white circle (open) indicates unmethylated at each given CpG site. (B) Chromatin immunoprecipitation–PCR analysis of histone
marks associated with ADAM19 in ovarian cancer cells. ChIP assays were performed with antibodies directed against trimethyl-H3K27,
dimethyl-H3K9, and HDAC1. Primers used to amplify two regions of ADAM19 are shown in Figure 3A. The relative binding of each
antibody to the corresponding region was measured by quantitative PCR. Error bar indicates SD calculated from triplicates. *P < .05.
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retinoic acid signaling resulted in epigenetic silencing of a down-
stream target gene, RARβ2. Targeted chromatin was first converted
from an active to an inactive state, followed by acquired DNA meth-
ylation and epigenetic silencing of the RARβ2 promoter CpG island
[42]. Zhang and Dufau [43] reported that epigenetic down-regulation
of the luteinizing hormone receptor was mediated through its inter-
action with upstream regulators of luteinizing hormone, EAR2, and
EAR3. Likewise, we previously demonstrated that disruption of es-
trogen signaling can lead to subsequent epigenetic silencing of a key
estrogen receptor downstream target gene, the progesterone receptor,
in breast cancer cells [44]. We further proposed a step-wise model
depicting epigenetic-mediated silencing of target genes that can result
from dysregulated signaling [44]. In that scenario, if signaling is re-
stored within a short period, the inactive transcriptional state can be
reversed. However, when transformed cells undergo long-term signal-
ing disruption and are maintained in a persistent state of inhibition,
polycomb repressors (e.g., EZH2, YY1, or EED) [49] and HDACs
are recruited to the target gene, a process that creates a repressive en-
vironment for permanent gene silencing. Subsequent recruitment of
DNA methyltransferases and methyl-CpG binding proteins causes
progressive accumulation of DNA methylation in the promoter of
the target gene. DNA methylation subsequently establishes a herita-
ble mark that eventually replaces some of the original repressors and
establishes an inactive heterochromatin state. Restoration of signal-
ing, however, does not result in gene reactivation, because an irrev-
ocable state of silencing has been permanently established [44].
Whereas the above model may explain why long-term absence of
estrogen signaling can result in accumulation of DNA methylation at
the progesterone receptor promoter in breast cancer [44], this equiva-
lent scenario was not observed at the ADAM19 promoter in ovarian
cancer cells insensitive to TGF-β signaling, because the ADAM19
CpG island remained virtually free of DNA methylation (Figure 5A).
In fact, the suppression of gene expression seemed to result from
chromatin remodeling associated with repressive chromatin marks,
including trimethyl-H3K27, as we and others have reported that
trimethyl-H3K27 can be linked to DNA methylation [50,51]. Our
recent findings also show that H3K27 methylation and DNA meth-
ylation can occur independently, in a promoter-specific manner
[52,53]. In addition, we speculate that in the absence of DNA meth-
ylation, ADMA19 is maintained at a less “rigid” state of silencing,
i.e., held in a basally low transcription state by trimethyl-H3K27
mark, a phenomenon recently described by McGarvey et al. [54]
and further supported by our current findings that TSA or DAC
treatment rendered ADAM19 reactivation (Figure 6). Interestingly,
A2780 and CP70 cells that bear a high level of repressive marks seem
to have greater gene reactivation after TSA treatment (Figure 6A).
Although the primary action of DAC is to remove DNA methylation
from the genome, our previous study demonstrated that combined
treatment of DAC and TSA can result in synergistic reactivation of
generally unmethylated genes [52]. Recently, the action mode of
DAC in reactivating epigenetically silenced genes has also been
shown to decrease histone H3K9 dimethylation by inhibiting G9A
histone methyltransferase [55], thus explaining why this drug can
partially restore the expression of the unmethylated ADMA19. It
may also explain why combinatorial treatment did not result in syn-
ergistic reactivation (data not shown) for the gene devoid of DNA
methylation because the drugs may act on the same mechanism, re-
ducing the repressive histone marks.
Although the specific role of ADAM19 in ovarian cancer remains
to be elucidated, increasing evidence supports a functional role for
ADAMs in tumor development and female malignancy [14,15], in-
cluding that ADAM15 and ADAM17 are associated with the pro-
gression of human breast cancer [18–20]. A main function of the
ADAMs family is shedding of membrane proteins [13]. In this re-
gard, ADAMs have been shown to cleave EGF receptor (EGFR)
ligand from the cell membrane and mediate EGFR signaling [56],
a process important in both normal and pathophysiological pro-
cesses [14]. The EGFR and its ligands have been strongly linked
to neoplastic transformation of the ovarian epithelium [57]. Yet,
whether ADAM19 is involved in this important molecular pathway
in ovarian cancer remains to be investigated.
Because tumor necrosis factor–related factors [58] are other ADAM
substrates, the roles that ADAMs play in inflammatory processes seem
to be important. Inflammatory stimuli, including tumor necrosis
factors, have been strongly implicated in the development of ovar-
ian cancer [59], presumably by their capacity to influence autocrine/
paracrine actions [4]. Thus, because the ADAMs are involved in bio-
logic processes highly relevant to the loss of growth regulation of the
OSE, including cell adhesion, motility, and cell-matrix interactions
[13], it seems reasonable to postulate that loss of ADAM19 function
could influence key cellular events within the ovarian microenviron-
ment. Supportive data implicating dysregulation or overexpression
of ADAM19 in disease exist, including a recent study demonstrating
aberrant ADAM19 expression in renal pathology [60]. In this regard, we
are further investigating the consequence(s) of loss of ADAM19 func-
tion by disrupting TGF-β/SMAD4 signaling in ADAM19-expressing
ovarian cancer cells.
Figure 6. Expression level of ADAM19 in ovarian cancer cell lines
treated with (A) TSA or (B) DAC. After the designated treatment
schemes, mRNAwere harvested, and expression levels of ADAM19
in treated cells were measured by quantitative RT-PCR. Error bar in-
dicates SD calculated from triplicates.
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The present study provides the rationale for determining what epi-
genetic mechanisms confer transcriptionally silent genes because of
dysregulated TGF-β signaling. Generalization of our model can be
achieved by performing genome-wide screening of chromatin mod-
ifications and DNA methylation using microarray-based approaches.
Future global analyses will contribute either to substantiate or to
tease out the step-wise epigenetic silencing described by us and others
[42–44]. Furthermore, these studies may shed light on how complex
epigenetic patterns, involving both histone modifications and DNA
methylation, are evolved in the absence of signaling and provide a
better understanding about the interplay among chromatin states,
transcriptional silencing, and neoplastic processes.
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Figure W1. Coomassie-stained membranes used to ensure equal quantity of protein sample loading for Western blot analysis shown in
Figure 2A.
Table W1. Primer Sequences Used in the Study.
Sequence Size (bp) Tm (°C)
ChIP-PCR
ADAM19 promoter F: TCACCTCTGAGTGTCACCCAAG 133 60
R: GATTTGTGGTGGACGCGG
ADAM19 exon F: TTTGTTCCCACGTTCTGCG 150 60
R: GAACGGCGGAAAGAGAAGC
ADAM19 intron F: GCTCCATGGGAGCAGTATTCAT 141 60
R: AGGCCAGGCTAGAGATATGCTG
RT-PCR
SMAD4 F: GTCTTTGATTTGCGTCAGTGTCAT 151 60
R: CAGCTGACAGACTGATAGCTGGAG
TGFβR1 F: AGTTAAGGCCAAATATCCCAAACAG 101 59
R: CCTAGCTGCTCCATTGGCAT
TGFβR2 F: ATTCCCAGCTTCTGGCTCAAC 123 60
R: CTCACTGAAGCGTTCTGCCAC
ADAM19 F: CAAGCTGAGGCAACAGTTCAGT 132 60
R: CGCAGGATTTCCGGAGTGT
GAPDH F: CCCCTTCATTGACCTCAACTACAT 135 60
R: CGCTCCTGGAAGATGGTGA
Bisulfite sequencing
ADAM19 promoter F: AGAGGGGTTTAGTTTAATTTTTAGAAG 340 60
R: CTCAACCATACCTACCCACTACCC
ADAM19 exon F: GGGTAGTGGGTAGGTATGGTTGAG 347 60
R: CRA CCTCTACCACCTCCCAAAAC
MSP
ADAM19 MF: AAGGCGTTTGGTATAGTGC 101 60
MR: AACGCGACCTATAAAAAATCG
UF: TTTAAGGTGTTTGGTATAGTGT 101 60
UR: AACACAACCTATAAAAAATCAAAA
SMAD4 mutation
Exon 9 F: TATTAAGCATGCTATACAATCTG 330 58
R: CTTCCACCCAGATTTCAATTC
seq: TTTTGACAACAAATAGAGCTTTAAGTC
Exon 11 F: CCAAAAGTGTGCAGCTTGTTG 554 58
R: CAGTTTCTGTCTGCTAGGAG
seq: TATTTTGTAGTCCACCATC
Table W2. Mutations in SMAD4 in Ovarian Cancer Cell Lines.
IOSE SKOV3 MCP3 MCP2 A2780 CP70
Exon 9 N N N N Codon 404 (TA insertion) N
Exon 11 N Intron/T to C N N N N
Figure W2. Chromatin immunoprecipitation–PCR analysis of ADAM19 in ovarian cancer cells. Chromatin immunoprecipitation assays
were performed with antibodies directed against DNA methyltransferase 1 (DNMT1; primers used to amplify two regions of ADAM19
are shown in Figure 2A). The relative binding of each antibody to the corresponding region was measured by quantitative PCR. Error bar
indicates SD calculated from triplicates. *P < .05.
